FDAnews
www.fdanews.com/articles/178378-new-york-ag-reviews-mylan-on-anticompetitive-sections-in-epipen-school-contracts

New York AG Reviews Mylan on Anticompetitive Sections in EpiPen School Contracts

September 12, 2016

The New York attorney general’s office is conducting an investigation to determine if Mylan engaged in anticompetitive practices when entering contracts to sell its allergy therapy EpiPen to schools.

New York Attorney General Eric Schneiderman contends the company may have included anticompetitive terms in sales contracts, after a preliminary investigation of EpiPen sales indicated that several local school systems may have reached such agreements.

Those initial findings prompted a complete investigation into the company’s contracts with schools, the attorney general said.

View today's stories